This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Fasting II Study

This study has been completed.
Sponsor:
Collaborator:
Intermountain Research and Medical Foundation
Information provided by (Responsible Party):
Intermountain Health Care, Inc.
ClinicalTrials.gov Identifier:
NCT01792986
First received: February 12, 2013
Last updated: February 10, 2017
Last verified: July 2013
February 12, 2013
February 10, 2017
February 2013
June 2013   (Final data collection date for primary outcome measure)
Difference in Mean Glucose Level Between Baseline and the End of the Sixth Week. [ Time Frame: 6 weeks ]
Difference in mean hemoglobin A1c level between baseline and the end of the fifth week. [ Time Frame: 5 weeks ]
Complete list of historical versions of study NCT01792986 on ClinicalTrials.gov Archive Site
  • Difference in Weight Between Baseline and the End of the Sixth Week [ Time Frame: 6 weeks ]
  • Difference in Low-density Lipoprotein Cholesterol (LDL-C) Between Baseline and the End of the Sixth Week. [ Time Frame: 6 weeks ]
  • Difference in Human Growth Hormone (HGH) Between Baseline and the End of the Sixth Week. [ Time Frame: 6 weeks ]
  • Difference in Red Blood Cell Count Between Baseline and the End of the Sixth Week. [ Time Frame: 6 weeks ]
Not Provided
Not Provided
Not Provided
 
The Fasting II Study
Preparatory Study to Determine Which Risk Markers May be Reduced by Fasting and Should be Evaluated in a Future Randomized Trial
This study will determine whether an intensive fasting protocol alters hemoglobin A1c measurements or other markers of metabolic and cardiovascular risk by performing a 5-week clinical trial of fasting among 12 pre-diabetic individuals or diabetics whose disease is controlled by diet. Participants will undergo a 5-week intervention of once-per-week 24-hour water-only fasting, including at baseline and at the end of the week for each week of the study (a total of 6 24-hour fasts).
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Other
  • Diabetes
  • Metabolic Diseases
Behavioral: water-only 24-hour fasting once per week for 6 weeks
water-only 24-hour fasting once per week for 6 weeks
Intervention: Behavioral: water-only 24-hour fasting once per week for 6 weeks
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
June 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or non-pregnant female, ≥30 and <70 years of age.
  2. Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
  3. Prior evidence of pre-diabetic state, with one of the following:

    1. Pre-diabetic with a measured hemoglobin A1c (HbA1c) ≥6.0% or fasting glucose >100 mg/dL without a clinical diabetes diagnosis
    2. Clinically-diagnosed type II diabetic with HbA1c ≥6.0% or fasting glucose ≥110 mg/dL and whose disease is controlled by diet alone.
  4. Evidence of metabolic syndrome by having at least 3 of the following 5 criteria:

    1. Fasting glucose level >100 mg/dL.
    2. Blood pressure ≥135 mmHg systolic or ≥85 mmHg diastolic, or use of an antihypertensive medication.
    3. High-density lipoprotein cholesterol <40 mg/dL in males or <50 mg/dL in females.
    4. Triglycerides ≥150 mg/dL or use of a cholesterol-lowering medication.
    5. Waist circumference >40 inches (102 cm) for males or >35 inches (88 cm) for females (or body mass index >25 kg/m2).

Exclusion Criteria:

  1. Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. Women of childbearing potential must be using adequate measures of contraception (as determined by the Principal Investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. Women of childbearing potential must have a negative pregnancy test at screen.
  2. Diabetics taking any of the following anti-diabetic medications: insulin, metformin, thiazolidinediones, sulfonylureas, alpha-glucosidase inhibitors, meglitinides, or incretins.
  3. Prior experience with fasting more than once per month (for 20 hours or more), on average during the last year.
  4. Very low body mass index (BMI) (<18.5 kg/m2) or high BMI (>40 kg/m2).
  5. Individuals who are nutritionally compromised, as assessed by the Principal Investigator.
  6. Any immunodeficiency or prior solid organ transplantation or renal disease.
  7. Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.
  8. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.
Sexes Eligible for Study: All
30 Years to 69 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01792986
1024469
No
Not Provided
Not Provided
Intermountain Health Care, Inc.
Intermountain Health Care, Inc.
Intermountain Research and Medical Foundation
Principal Investigator: Benjamin D Horne, PhD, MPH Intermountain Health Care, Inc.
Intermountain Health Care, Inc.
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP